Nerve Injury Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 04, 2015 -- The report “Nerve Injury – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Nerve Injury. Nerves are easily broken and can be damaged by pressure, stretching or cutting. An injury to a nerve can result in a problem with the muscle or in a loss of sensation. Classification of nerve injury depends upon the nerve components affected, loss of functionality and the ability to recover instinctively. Peripheral nerve injury may result in demyelination, axonal degeneration or both.
The report also reviews key players involved in the therapeutic development for Nerve Injury and special features on late-stage and discontinued projects. Companies discussed in this Nerve Injury – Pipeline Review, H1 2015 report include Acorda Therapeutics, Inc., Calico LLC, Convergence Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Kolon Life Science, Inc., Medtronic, Inc., Neuralstem, Inc., Neurotune AG, Pfizer Inc.
Pressure or stretching injuries can cause fibers within the nerve to break. Common causes of nerve injuries include laceration, focal contusion, stretch/traction injury, compression, drug injection injury, electrical injury. Symptoms of a nerve injury include alteration of sensation, loss of muscle power, pain. Early diagnosis and treatment can prevent complications and permanent injury. Nonsurgical treatment for nerve injuries may include acupuncture, massage therapy, medication, orthotics, physical therapy and rehabilitation and weight loss management. Drugs profiled discuss in this report include 3K3A-APC, cimaglermin alfa, CLP-257, CNV-1014802, KLS-Nst, MDT-15, NSI-566, NT-1654, Small Molecules to Activate NAMPT for Neurological Disorders, Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury abd WAY-258131. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269595 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
List of Tables
Number of Products under Development for Nerve Injury, H1 2015
Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Nerve Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015
Nerve Injury - Pipeline by Calico LLC, H1 2015
Nerve Injury - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015
Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Nerve Injury - Pipeline by Kolon Life Science, Inc., H1 2015
Nerve Injury - Pipeline by Medtronic, Inc., H1 2015
Nerve Injury - Pipeline by Neuralstem, Inc., H1 2015
Nerve Injury - Pipeline by Neurotune AG, H1 2015
Nerve Injury - Pipeline by Pfizer Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Nerve Injury Therapeutics - Recent Pipeline Updates, H1 2015
Nerve Injury - Dormant Projects, H1 2015
Nerve Injury - Discontinued Products, H1 2015
Explore more reports on Neurology Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics/ .
More reports on Neurology Therapeutics Market
Tardive Dyskinesia – Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia. Companies discussed in this Tardive Dyskinesia – Pipeline Review, H1 2015 report include Auspex Pharmaceuticals, Inc., Contera Pharma ApS, Medicure Inc., Neurocrine Biosciences, Inc., Synchroneuron Inc.
Drugs profiled discuss in this report include acamprosate calcium SR, Drugs for Tardive Dyskinesia, dutetrabenazine ER, Tardoxal, valbenazine. Complete report details @ http://www.rnrmarketresearch.com/tardive-dyskinesia-pipeline-review-h1-2015-market-report.html .
Status Epilepticus – Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Status Epilepticus. Companies and drugs profiled discussed in this report includes Ligand Pharmaceuticals, Inc., Sage Therapeutics, ADD-405008, fosphenytoin sodium, SAGE-217, SAGE-547, SAGE-689, SGE-102, TG-4155. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete report details @ http://www.rnrmarketresearch.com/status-epilepticus-pipeline-review-h2-2014-market-report.html .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article